Regenerative medicine for the heart

Curing heart failure,
one stage at a time

Organamet Bio is advancing a sequential pipeline of first-in-class bioengineered therapies across the full spectrum of heart failure — led by Lami-Pro™, the first disease-modifying biologic for heart failure with preserved ejection fraction (HFpEF), a market with zero approved competitors.

Explore the pipeline → Investor access
$40MM Post-Seed + Series A HQ at ARMI | BioFabUSA Zero approved HFpEF biologics
A focused strategy

From a market-ready pipeline to a moonshot

Our founding vision — a fully bioengineered, patient-specific heart — remains the endgame. But great science reaches patients only when it is sequenced wisely.

Organamet leads with the fastest, most capital-efficient product in our portfolio: Lami-Pro™, an injectable biologic for HFpEF. It reaches the clinic first, validates our intellectual-property platform, and generates the licensing revenue that funds and de-risks the larger prizes behind it — Ventri-Pro™ and Your-Heart™.

Why lead with Lami-Pro™? →
Sequential commercialization
Launch first. Validate. Fund what's next.
1
Lami-Pro™
HFpEF · injectable biologic · lead
2
Ventri-Pro™
HFrEF · bioengineered cardiac-derived patch
3
Your-Heart™
End-stage HF · patient-specific heart
The pipeline

Three products across the full heart-failure spectrum

One regenerative platform, anchored by the decellularization and bioengineering patents of Dr. Doris Taylor.

Lead
HFpEF

Lami-Pro™

An injectable, patent-pending biologic delivered into cardiac muscle — restoring native proteins, reducing inflammation and fibrosis, and restoring relaxation. A one-time treatment designed to reverse the disease.

First-in-human in ~3 years
Near-term
HFrEF

Ventri-Pro™

A bioengineered cardiac-derived patch that halts dilated (HFrEF) heart-failure progression — stabilizing the heart, promoting vascularization, and creating an environment for regeneration before irreversible damage.

Proven in preclinical models
Moonshot
End-stage HF

Your-Heart™

A fully bioengineered, patient-specific heart built from a patient's own cells — eliminating rejection, immunosuppression, and the donor-supply ceiling. A definitive cure for end-stage heart failure.

The platform endgame
The opportunity

The deadliest, costliest disease in the world

Heart failure is the leading cause of death globally — and its largest segment has no disease-modifying therapy at all.

64M
people live with heart failure today
Projected to reach 75M by 2030
~$48B
heart-failure therapeutics market by 2030
From ~$26B in 2024 · ~10.5% CAGR
0
FDA-approved disease-modifying biologics for HFpEF
Roughly half of all heart failure
Trusted partners

Built on a foundation of advanced manufacturing

ARMI | BioFabUSA Advanced Solutions Life Sciences DEKA Research BioAssemblyBot® University of Minnesota & Texas Heart Institute lineage